Association Between Serum Uric Acid Levels and Cardiovascular Risk in Hypertensive Patients

Abstract

This meta-analysis assesses hypertension-associated cardiovascular risk with serum uric acid (SUA) levels. Studies were systematically identified through PubMed, Scopus, Embase, and Web of Science, focusing on research from 2021 to 2025, both observational and interventional. Studies adduced through random-effects models demonstrated that cardiovascular event risks (stroke, myocardial infarction, and heart failure) considerably increased with higher levels of uric acid. The relationship was persistent when age, renal function, and metabolic state were factored in. Hyperuricemia deteriorates renal function, thereby contributing to, and not limited to, endothelial dysfunction, oxidative stress, systemic inflammation, and hypertension. Although urate-lowering agents improve vascular function, long-term adverse cardiovascular outcomes remain in question. The control and supervision of SUA levels in hypertensives will likely improve risk stratification and the risks of adverse cardiovascular event outcomes.